AGN-223575 ophthalmic suspension
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AGN-223575 ophthalmic suspension, covering 2019-04-05 to 2019-04-05. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease [Phase 2]